EHA 2025 | Improving the management of relapsed and newly diagnosed pediatric ALL
In this video, Erica Brivio, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, provides insight into unanswered questions that remain in the management of pediatric acute lymphoblastic leukemia (ALL), both in the relapsed and newly diagnosed settings. She suggests that tailoring the treatment of relapsed patients based on their disease subtype may improve outcomes. Also, Dr Brivio emphasizes the need to investigate the feasibility of replacing chemotherapy with immunotherapy in the frontline setting. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think about the challenges in relapse children, we are moving towards more targeted treatment, so try to divide these relapsed children into subgroups and for every group try to find the best treatment for them, like there are KMT2A-rearranged patients that are very difficult to treat. Probably we need to integrate with menin inhibitors to try to treat them in the best way, try to find the best way to use CAR-T treatment, which is also very effective...
So I think about the challenges in relapse children, we are moving towards more targeted treatment, so try to divide these relapsed children into subgroups and for every group try to find the best treatment for them, like there are KMT2A-rearranged patients that are very difficult to treat. Probably we need to integrate with menin inhibitors to try to treat them in the best way, try to find the best way to use CAR-T treatment, which is also very effective. But still, probably we need to find the right moment, right population to use it in the best effective way.
And about frontline, it is to find the right combination to use these immunotherapies in the best way because, of course, they are very promising and we know a lot about relapsed children but we know only a few things about their use in frontline. If we reduce chemotherapy and we use immunotherapy instead, we don’t know yet if we will get the same results. So our challenge is to reduce chemotherapy, so not to add immunotherapy, but to use immunotherapy instead of chemotherapy. But this is the question we need to answer in the coming years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Institutional funding: Pfizer.
